BEERSE, Belgio--(BUSINESS WIRE)--Le aziende farmaceutiche Janssen di Johnson & Johnson hanno oggi annunciato che il Comitato per i medicinali per uso umano (CHMP) dell'Agenzia europea per i medicinali (EMA) ha emesso un parere positivo sull'estensione dell'autorizzazione alla commercializzazione di Imbruvica® (ibrutinib) per due indicazioni. Una è per l'uso di ibrutinib in combinazione con obinutuzumab per il trattamento dei pazienti adulti affetti da leucemia linfocitica cronica (LLC) non
Mon Jul 01, 2019 16:40
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--AMPHIVENA DATA AT EHA
Mon Jul 01, 2019 16:15
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Instem is pleased to announce that NOTOCORD, an Instem Company, has been awarded an EU Horizon 2020 Research Grant.
Mon Jul 01, 2019 16:06
BEERSE, Bélgica--(BUSINESS WIRE)--Las compañías farmacéuticas Janssen de Johnson & Johnson han anunciado que el Comité de Medicamentos de Uso Humano (CHMP) de la Agencia Europea de Medicamentos (EMA) ha recomendado ampliar la autorización de comercialización existente para Imbruvica® (ibrutinib) en dos indicaciones. Una recomendación es para el uso de ibrutinib en combinación con obinutuzumab en pacientes adultos con leucemia linfocítica crónica (LLC) no tratada previamente.1 La segunda es
Mon Jul 01, 2019 16:06
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology has submitted a supplemental NDA to the U.S. FDA for neratinib in combination with capecitabine for the treatment of breast cancer
Mon Jul 01, 2019 15:00
INGELHEIM, Germany & SEOUL, South Korea--(BUSINESS WIRE)--Boehringer Ingelheim and Yuhan Corporation today announced a collaboration and license agreement for the development of a first-in-class dual agonist for the treatment of NASH and related liver diseases that combines GLP-1 and FGF21 activity in one molecule. The collaboration brings together Yuhan Corporation’s expertise in FGF21 biology, obesity and NASH with Boehringer Ingelheim’s pharmaceutical expertise and commitment to bringing inn
Mon Jul 01, 2019 15:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Semma Therapeutics, Inc., a biotechnology company pioneering the curative use of stem cells in regenerative medicine, today announced the achievement of pre-clinical proof-of-concept based on data from its two lead programs for type 1 diabetes testing stem cell-derived islets (SC-islets) in both non-human primates and pigs. The data were presented by Felicia Pagliuca, Ph.D., Vice President of Cell Biology Research and Development, on Saturday, June 29th in a p
Mon Jul 01, 2019 15:00
WALNUT CREEK, Calif.--(BUSINESS WIRE)--Synergys announces second Phase 1 SBIR funding from NIH for development of vasculogenic mimicry-blocking antibody fusion product for ovarian cancer.
Mon Jul 01, 2019 15:00
NEW YORK--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it joined the broad-market Russell 3000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the close of the US market on June 28, 2019. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 10, ranking them by total market capitalization. M
Mon Jul 01, 2019 15:00
CAMBRIDGE, U.K., & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics announces the successful completion of Oxurion’s Phase I clinical trial evaluating the safety and tolerability of THR-149.
Mon Jul 01, 2019 14:30
GAITHERSBURG, Md.--(BUSINESS WIRE)--Viela Bio today announced the appointment of Mitchell Chan as Chief Financial Officer, effective July 1. In this role, he will be responsible for leading corporate financing, financial operations, treasury, investor relations, corporate communications and corporate strategy. Previously, Mr. Chan served as Viela’s Vice President, Head of Finance & Corporate Strategy. “We are pleased to announce Mitch’s appointment to the CFO position,” said Bing Yao, Ph.D.
Mon Jul 01, 2019 14:00
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου